Literature DB >> 10086095

[Pregnancy outcome after ecstasy use; 43 cases followed by the Teratology Information Service of the National Institute for Public Health and Environment (RIVM)].

M M van Tonningen-van Driel1, J M Garbis-Berkvens, W E Reuvers-Lodewijks.   

Abstract

OBJECTIVE: To determine if use of ecstacy during pregnancy has any harmful effects on pregnancy and the (unborn) child.
DESIGN: Prospective, descriptive.
METHODS: After the Teratology Information Service of the National Institute of Public Health and the Environment. Bilthoven, the Netherlands, was approached by a physician or midwife for information, the pregnancies that involved the use of ecstacy were followed by a follow-up questionnaire one month after the estimated date of birth.
RESULTS: A total of 49 pregnancies were followed. For 43 women, exposed early in pregnancy, data on course of pregnancy and health of baby are known. There were 3 elective terminations of pregnancy and 2 spontaneous abortions. There were 40 live-born babies (including one set of triplets); one of them had a congenital cardiac malformation. Beside ecstacy the mothers frequently also used other substances potentially harmful to pregnancy and child. The pregnancies were often unplanned; previous pregnancies had frequently been terminated.
CONCLUSION: The sample size was too small to draw conclusions. As yet spontaneous abortions and congenital malformations did not appear to occur more frequently in pregnancies with use of ecstacy. The lifestyle of the ecstacy users seemed to be potentially harmful for pregnancy and child.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086095

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  9 in total

Review 1.  Developmental consequences of fetal exposure to drugs: what we know and what we still must learn.

Authors:  Emily J Ross; Devon L Graham; Kelli M Money; Gregg D Stanwood
Journal:  Neuropsychopharmacology       Date:  2014-06-18       Impact factor: 7.853

2.  In-utero exposure to the popular 'recreational' drugs MDMA (Ecstasy) and Methamphetamine (Ice, crystal): preliminary findings.

Authors:  Derek G Moore; John J D Turner; Julia E Goodwin; Sarah E Fulton; Lynn T Singer; Andrew C Parrott
Journal:  Clin Dev Med       Date:  2011-02

3.  One-year outcomes of prenatal exposure to MDMA and other recreational drugs.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Pediatrics       Date:  2012-08-20       Impact factor: 7.124

4.  A case control study to examine the pharmacological factors underlying ventricular septal defects in the North of England.

Authors:  D N Bateman; P R McElhatton; D Dickinson; C Wren; J N S Matthews; M O'Keeffe; S H L Thomas
Journal:  Eur J Clin Pharmacol       Date:  2004-09-23       Impact factor: 2.953

Review 5.  Developmental effects of 3,4-methylenedioxymethamphetamine: a review.

Authors:  Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Behav Pharmacol       Date:  2008-03       Impact factor: 2.293

6.  Motor delays in MDMA (ecstasy) exposed infants persist to 2 years.

Authors:  Lynn T Singer; Derek G Moore; Meeyoung O Min; Julia Goodwin; John J D Turner; Sarah Fulton; Andrew C Parrott
Journal:  Neurotoxicol Teratol       Date:  2016-01-21       Impact factor: 3.763

7.  Neonatal citalopram treatment inhibits the 5-HT depleting effects of MDMA exposure in rats.

Authors:  Tori L Schaefer; Curtis E Grace; Matthew R Skelton; Devon L Graham; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  ACS Chem Neurosci       Date:  2011-10-21       Impact factor: 4.418

8.  Long-term behavioral consequences of prenatal MDMA exposure.

Authors:  Valerie B Thompson; Justin Heiman; James B Chambers; Stephen C Benoit; William R Buesing; Mantana K Norman; Andrew B Norman; Jack W Lipton
Journal:  Physiol Behav       Date:  2008-12-31

9.  Neuronal reorganization in adult rats neonatally exposed to (±)-3,4-methylenedioxymethamphetamine.

Authors:  Michael T Williams; Matthew R Skelton; Ian D Longacre; Kimberly N Huggins; Amanda M Maple; Charles V Vorhees; Russell W Brown
Journal:  Toxicol Rep       Date:  2014
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.